Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63


Delayed London Stock Exchange  -  11:35 2022-10-06 am EDT
1322.60 GBX   -0.48%
10/05GSK plc Announces Positive Headline Results from Perla, the Phase II Trial of Jemperli (Dostarlimab) Plus Chemotherapy in Patients with Metastatic Non-Squamous Non-Small Cell Lung Cancer
10/05ETF Preview: ETFs, Futures Decline Pre-Bell After Private Payroll, Trade Deficit Reports
10/05GSK Says Non-Small Cell Lung Cancer Therapeutic Candidate Met Primary Endpoint in Phase 2 Study
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : GSK announces independent Consumer Healthcare company is to be called Haleon

02/22/2022 | 09:12am EDT

For media and investors only
Issued: London, UK

  • Haleon will be a new world-leader in consumer health with an exceptional portfolio of category-leading brands, including Sensodyne, Voltaren, Panadol and Centrum
  • Business is on track to demerge and list as a new company in mid-2022

GlaxoSmithKline plc (GSK) today announced that the new company, to result from the proposed demerger of Consumer Healthcare from GSK in mid-2022, will be called Haleon.

Haleon (pronounced "Hay-Lee-On") is inspired by the merging of the words 'Hale', which is an old English word that means 'in good health' and Leon, which is associated with the word 'strength'. The new brand identity was developed with input from employees, healthcare practitioners and consumers and will be deployed in more than 100 markets around the world where the business operates.

The creation of Haleon results from a series of successful investments and strategic changes to GSK's consumer health business over the last 8 years, including integrations of the consumer product portfolios from Novartis and Pfizer. It is now a highly valuable and focused global business generating annual sales of approximately £10 billion[1].

As a standalone company, Haleon will be a new world-leader in consumer healthcare, offering a compelling proposition - to bring deep human understanding together with trusted science - to deliver better everyday health with humanity.

Brian McNamara, Chief Executive Officer Designate, Haleon,said: "Introducing Haleon to the world marks another step in our journey to become a new, standalone company. Our name is grounded in our purpose to deliver better everyday health with humanity and to be a world-leader in consumer healthcare. We are on track to launch Haleon in mid-2022 and our business momentum is strong. We look forward to updating investors and analysts more on this at our capital markets event at the end of February."

Emma Walmsley, Chief Executive Officer, GSK, said: "Haleon brings to life years of hard work by many outstanding people to build this new company purely dedicated to everyday health. Haleon has enormous potential to improve health and wellbeing across the world with strong prospects for growth, and through listing will unlock significant value for GSK shareholders."

Haleon will have a world-class portfolio of category-leading global brands, including Sensodyne, Voltaren, Panadol and Centrum. Its brands are trusted by healthcare professionals, customers and people worldwide to improve the health and wellbeing of individuals and their communities. Demand from the £150 billion consumer healthcare sector is strong, reflecting an increased focus on health and wellness, significant demand from an ageing population and emerging middle-class, and unmet consumer needs. The business is therefore well-positioned to deliver human health impact and to sustainably grow ahead of the market in the years to come.

The new name was announced as part of a global celebration for all of the people working in GSK Consumer Healthcare earlier today. Employees from around the world had the opportunity to engage with the new name and brand identity which seeks to bring to life the company's purpose and growth ambitions.

The name was also announced in advance of GSK hosting a Consumer Healthcare Capital Markets Day for investors and analysts on Monday 28 February, to provide details on the overall strategy, capabilities and operations of Haleon, including detailed financial information and growth ambitions of the business. For prospective investors, Haleon will offer attractive organic sales growth, operating margin expansion and consistent high cash generation.

Notes to editors

  • As set out at GSK's Investor Update in June 2021, subject to approval from shareholders, the separation of Consumer Healthcare will be by way of a demerger in mid-2022 of at least 80% of GSK's holding to shareholders.
  • Haleon will be headquartered in Weybridge, UK, and is expected to attain a premium listing on the London Stock Exchange, with ADRs to be listed in the US.
  • The new Weybridge campus is expected to open at the end of 2024 and, alongside being the new company's corporate headquarters, will be a centre of R&D and innovation, and home to a new state-of-the-art Shopper Science Lab.
  • In July 2021, the Board of GSK confirmed Brian McNamara as CEO Designate and in December 2021, announced the appointment of Sir Dave Lewis as Chair Designate of the new company to result from the proposed demerger of Consumer Healthcare from GSK.

About GSK

GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any impacts of the COVID-19 pandemic.


[1]Sales in FY2021 £9.6 billion, including Brands divested/under review; £9.5bn continuing sales


GSK - GlaxoSmithKline plc published this content on 22 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 February 2022 14:11:05 UTC.

© Publicnow 2022
All news about GSK PLC
10/05GSK plc Announces Positive Headline Results from Perla, the Phase II Trial of Jemperli ..
10/05ETF Preview: ETFs, Futures Decline Pre-Bell After Private Payroll, Trade Def..
10/05GSK Says Non-Small Cell Lung Cancer Therapeutic Candidate Met Primary Endpoint in Phase..
10/05GSK's Lung Cancer Combination Therapy Shows Shrunken Tumors In Mid-stage Study
10/05Gsk : announces positive headline results from PERLA, the phase II trial of Jemperli (dost..
10/04Vir Biotech gets U.S. funding for flu-prevention antibody
10/04GSK : JP Morgan sticks Neutral
10/03GSK : Deutsche Bank reiterates its Neutral rating
09/30GLAXOSMITHKLINE PLC : Monthly statement on voting rights
09/29Haleon Launches Exchange Offers for Seven Series of Notes
More news
Analyst Recommendations on GSK PLC
More recommendations
Sales 2022 28 236 M 31 592 M 31 592 M
Net income 2022 4 470 M 5 001 M 5 001 M
Net Debt 2022 13 723 M 15 354 M 15 354 M
P/E ratio 2022 11,5x
Yield 2022 4,59%
Capitalization 53 543 M 59 907 M 59 907 M
EV / Sales 2022 2,38x
EV / Sales 2023 2,26x
Nbr of Employees 90 096
Free-Float 93,7%
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 1 322,60 GBX
Average target price 1 835,51 GBX
Spread / Average Target 38,8%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-19.53%60 521
JOHNSON & JOHNSON-5.35%434 104
ROCHE HOLDING AG-13.48%273 724
ABBVIE INC.5.86%253 421
PFIZER, INC.-27.03%247 617